0QFK Stock Overview
A biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Celyad Oncology SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.37 |
| 52 Week High | €1.23 |
| 52 Week Low | €0.35 |
| Beta | 1.3 |
| 11 Month Change | 0% |
| 3 Month Change | -0.27% |
| 1 Year Change | -50.54% |
| 33 Year Change | -93.48% |
| 5 Year Change | -98.00% |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QFK | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -0.8% |
| 1Y | -50.5% | -16.8% | 9.2% |
Return vs Industry: 0QFK underperformed the UK Biotechs industry which returned -30.1% over the past year.
Return vs Market: 0QFK underperformed the UK Market which returned -0.8% over the past year.
Price Volatility
| 0QFK volatility | |
|---|---|
| 0QFK Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QFK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QFK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 18 | Michel E. Lussier | www.celyad.com |
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets.
Celyad Oncology SA Fundamentals Summary
| 0QFK fundamental statistics | |
|---|---|
| Market cap | €14.07m |
| Earnings (TTM) | -€8.45m |
| Revenue (TTM) | €102.00k |
138.1x
P/S Ratio-1.7x
P/E RatioIs 0QFK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QFK income statement (TTM) | |
|---|---|
| Revenue | €102.00k |
| Cost of Revenue | €69.00k |
| Gross Profit | €33.00k |
| Other Expenses | €8.48m |
| Earnings | -€8.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 32.35% |
| Net Profit Margin | -8,282.35% |
| Debt/Equity Ratio | 0% |
How did 0QFK perform over the long term?
See historical performance and comparison